Immune safety of a novel oncolytic mutant M1 after administration In Vivo

The aim of this study was to evaluate the safety and efficiency of a novel,oncolytic adenovirus mutant M1 administered in conjunction with immunosuppressive agents.Animal models were established by administering purified M1 either intravenously or retroperitoneally.At different time points,blood samples were taken from the mice for testing of liver and renal function.Microscopic examination of the liver was performed to observe pathological changes.Immunohistochemical analyses were used to evaluate the expression of the adenovirus in the liver.Lymphocyte recruitment to the liver and the activation of adenovirus specific T cells were also analyzed.No signs of general toxicity were observed,but transient increases in ALT and Scr were observed following the administration of M1.Microscopic examination revealed a mild inflammatory response in the liver.Compared to intravenous injection,higher expression levels of adenoviral proteins were observed after retroperitoneal injection.Combined treatment with cyclosporine A resolved the liver and kidney dysfunction and increased the concentration of the adenovirus in the liver.The use of the novel oncolytic adenovirus mutant M1 in vivo is safe,and the combined administration of M1 with immunosuppressive agents was able to enhance the effectiveness and safety profile of M1.     

移植日C反应蛋白水平对异基因造血干细胞移植早期感染及预后的预测意义

目的探讨移植日C反应蛋白（CRP）水平对异基因造血干细胞移植早期败血症等感染事件发生的预测意义。方法回
顾性分析78 例异基因移植患者病例资料,采用受试者工作特征曲线（ROC）评估CRP诊断移植早期败血症的临床参考值及
相应灵敏度和特异度,以所得临床参考值为临界值将病例资料分为低CRP组和高CRP组,分析比较两组间的移植相关并发
症及总生存（OS）和复发率等。结果CRP 诊断移植早期败血症的临床参考值为23.3 mg/L（AUC=0.735,P=0.001,95% CI
0.623~0.848）,相应灵敏度和特异度分别为0.793 和0.592;高CRP组粒系平均重建时间较低CRP组延迟0.71 d（P=0.237）,巨
核系平均重建时间显著延迟4.09 d（P=0.048）;高CRP组移植早期败血症及巨细胞病毒（CMV）血症发生率较低CRP组显著
增高（53.5% vs 17.1%,P=0.001;72.1% vs 37.1%,P=0.003）,但两组间EB病毒（EBV）血症、肺部侵袭性真菌感染及急性移植
物抗宿主病（aGVHD）发生率无统计学差异（41.9% vs 22.9%,P=0.094;14.0% vs 5.7%,P=0.285, 51.2% vs 45.7,P=0.656）;高
CRP 组中位随访318（7~773）d,低CRP 组中位随访299（78~747）d,高CRP 组2 年OS 率较低CRP 组显著降低（42.5% vs
78.4%,P=0.022）,高CRP组2 年累计复发率较低CRP组高（52.3% vs 19.8%,P=0.235）,但差异无统计学意义;Logistic 多因素
分析显示高CRP水平是移植早期败血症的独立危险因素（OR=5.090,95% CI 1.115~23.229,P=0.036）。结论移植日CRP水
平对异基因造血干细胞移植早期败血症有一定的预测意义,高CRP水平提示较高的移植早期败血症和CMV血症发生率
以及较差的预后。
     

Tim-3在宫颈癌组织中的表达及其与恶性进展的关系

目的探讨宫颈癌细胞表达T-cell immunoglobulin and mucin domain containing 3 protein（Tim-3）与宫颈癌恶性进展的关系。方法用反转录PCR（RT-PCR）、Western blot和共聚焦显微镜检测宫颈癌细胞系HeLa和SiHa中Tim-3基因和蛋白的表达及其胞内定位;用免疫组织化学法检测43例宫颈癌组织中Tim-3的表达,并分析其与临床分期、组织分型、转移等相关性。结果证实HeLa和SiHa两个宫颈癌细胞系均表达Tim-3,在前者Tim-3分布于胞质,而在后者则分布于核内及其周围。在宫颈癌患者病理标本中可见癌巢和肿瘤血管高表达Tim-3,且Tim-3表达强度与与临床分期、组织分型和转移相关。结论宫颈癌细胞及血管内皮细胞均高表达Tim-3,且Tim-3表达强度与宫颈癌恶性进展及转移高度相关。     

套细胞淋巴瘤并发血栓性血小板减少性紫癜报告及文献复习

目前报道的淋巴瘤并发血栓性血小板减少性紫癜（thrombotic thrombocytopenic purpura,TTP）的病例少见,最早见于1980年Crain等报道的1例伴皮肤累及的霍奇金淋巴瘤（ⅣB期）患者行切脾治疗后并发TTP病例,国内外尚未见套细胞淋巴瘤（mantle cell lymphoma,MCL）并发TTP的报道。现将我科诊治的1例MCL并发TTP报道如下。     

应激致下丘脑综合征1例及文献复习

下丘脑综合征（hypothalamus syndrome）系由多种病因累及下丘脑所致的疾病,临床表现多样,但因应激出现间断高热的患者少见,本文报道如下。临床资料患者,女,13岁,因间断发热近3月入院。患者3月前,进食冷牛奶和冷鸡腿后,出现恶心、呕吐,非喷射状,呕吐物为胃内容物,1h后出现发热,体温初